KDR and ovarian cancer: By binding to VEGFR-2, apatinib inhibits the effects of VEGF binding and subsequent VEGFR-2 autophosphorylation.[8] Although apatinib has shown promising therapeutic effects against diverse tumor types in several phase II clinical trials, it still remains unknown whether apatinib has an antitumor effect in patients with ovarian cancer.[8,9]